Details

Autor(en) / Beteiligte

• Bon, Giulia
• Di Lisa, Francesca Sofia
• Filomeno, Lorena
• Arcuri, Teresa
• Krasniqi, Eriseld
• Pizzuti, Laura
• Barba, Maddalena
• Messina, Beatrice
• Schiavoni, Giulia
• Sanguineti, Giuseppe
• Botti, Claudio
• Cappelli, Sonia
• Pelle, Fabio
• Cavicchi, Flavia
• Puccica, Ilaria
• Costantini, Maurizio
• Perracchio, Letizia
• Maugeri‐Saccà, Marcello
• Ciliberto, Gennaro
• Vici, Patrizia

Titel

HER2 mutation as an emerging target in advanced breast cancer

Ist Teil von

• Cancer science, 2024-07, Vol.115 (7), p.2147-2158

Ort / Verlag

England: John Wiley & Sons, Inc

Erscheinungsjahr

2024

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• HER2 activating mutations have emerged as oncogenic drivers and therapeutic targets in a variety of human tumors. In breast cancer, these deregulations occur at low frequency, and are mostly detected in HER2‐nonamplified, metastatic disease. Preclinical evidence has clarified the role of hotspot mutations in HER2 constitutive activation, defining them as an alternative mechanism to HER2 gene amplification. Furthermore, recent clinical studies have indicated the emergence of newly acquired HER2 deregulations in significant proportions of breast cancer patients who experience disease progression following both endocrine and HER2‐targeted therapies. As the involvement of HER2 mutation in therapy resistance may profoundly impact patient outcomes on successive therapies, several clinical trials are currently investigating the efficacy of various HER2‐targeted drugs in HER2‐mutant breast cancer. In this review, we firstly summarize the structural organization of the HER2 oncogene and its historical impact on breast cancer prognosis and therapeutic advancement. Then, we provide an overview of the frequencies and functional relevance of clinically recurrent HER2 mutations in breast cancer with a special focus on their role in therapeutic resistance. Finally, we provide a collection of the clinical trials that are currently exploring novel therapeutic approaches for this patient subset and discuss the related perspectives and challenges. Although occurring at low frequencies, HER2 activating mutations have emerged as oncogenic drivers and therapeutic targets in breast cancer. Outlining a role in therapeutic resistance, newly acquired HER2 deregulations are frequently detected in patients who experience disease progression following both endocrine and HER2‐targeted therapies. Novel therapeutic approaches for this patient subset are currently under consideration, and further investigations are needed.